190 related articles for article (PubMed ID: 11549670)
1. Visceral adipose tissue and metabolic complications of obesity are reduced in Prader-Willi syndrome female adults: evidence for novel influences on body fat distribution.
Goldstone AP; Thomas EL; Brynes AE; Bell JD; Frost G; Saeed N; Hajnal JV; Howard JK; Holland A; Bloom SR
J Clin Endocrinol Metab; 2001 Sep; 86(9):4330-8. PubMed ID: 11549670
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance and obesity-related factors in Prader-Willi syndrome: comparison with obese subjects.
Talebizadeh Z; Butler MG
Clin Genet; 2005 Mar; 67(3):230-9. PubMed ID: 15691361
[TBL] [Abstract][Full Text] [Related]
3. Elevated fasting plasma ghrelin in prader-willi syndrome adults is not solely explained by their reduced visceral adiposity and insulin resistance.
Goldstone AP; Thomas EL; Brynes AE; Castroman G; Edwards R; Ghatei MA; Frost G; Holland AJ; Grossman AB; Korbonits M; Bloom SR; Bell JD
J Clin Endocrinol Metab; 2004 Apr; 89(4):1718-26. PubMed ID: 15070936
[TBL] [Abstract][Full Text] [Related]
4. Metabolic and adipose tissue signatures in adults with Prader-Willi syndrome: a model of extreme adiposity.
Lacroix D; Moutel S; Coupaye M; Huvenne H; Faucher P; Pelloux V; Rouault C; Bastard JP; Cagnard N; Dubern B; Clément K; Poitou C
J Clin Endocrinol Metab; 2015 Mar; 100(3):850-9. PubMed ID: 25478934
[TBL] [Abstract][Full Text] [Related]
5. The use of magnetic resonance imaging to characterize abnormal body composition phenotypes in youth with Prader-Willi syndrome.
Orsso CE; Mackenzie M; Alberga AS; Sharma AM; Richer L; Rubin DA; Prado CM; Haqq AM
Metabolism; 2017 Apr; 69():67-75. PubMed ID: 28285653
[TBL] [Abstract][Full Text] [Related]
6. Metabolic profile and body composition in adults with Prader-Willi syndrome and severe obesity.
Höybye C; Hilding A; Jacobsson H; Thorén M
J Clin Endocrinol Metab; 2002 Aug; 87(8):3590-7. PubMed ID: 12161480
[TBL] [Abstract][Full Text] [Related]
7. Body composition, endocrine and metabolic profiles in adults with Prader-Willi syndrome.
Sode-Carlsen R; Farholt S; Rabben KF; Bollerslev J; Schreiner T; Jurik AG; Christiansen JS; Höybye C
Growth Horm IGF Res; 2010 Jun; 20(3):179-84. PubMed ID: 20199883
[TBL] [Abstract][Full Text] [Related]
8. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women?
Brochu M; Tchernof A; Dionne IJ; Sites CK; Eltabbakh GH; Sims EA; Poehlman ET
J Clin Endocrinol Metab; 2001 Mar; 86(3):1020-5. PubMed ID: 11238480
[TBL] [Abstract][Full Text] [Related]
9. Circulating adiponectin levels, body composition and obesity-related variables in Prader-Willi syndrome: comparison with obese subjects.
Kennedy L; Bittel DC; Kibiryeva N; Kalra SP; Torto R; Butler MG
Int J Obes (Lond); 2006 Feb; 30(2):382-7. PubMed ID: 16231029
[TBL] [Abstract][Full Text] [Related]
10. Comparison of body composition, basal metabolic rate and metabolic outcomes of adults with Prader Willi syndrome or lesional hypothalamic disease, with primary obesity.
Lloret-Linares C; Faucher P; Coupaye M; Alili R; Green A; Basdevant A; Clément K; Poitou C
Int J Obes (Lond); 2013 Sep; 37(9):1198-203. PubMed ID: 23318724
[TBL] [Abstract][Full Text] [Related]
11. The relationship between metabolic syndrome, cytokines and physical activity in obese youth with and without Prader-Willi syndrome.
McAlister KL; Fisher KL; Dumont-Driscoll MC; Rubin DA
J Pediatr Endocrinol Metab; 2018 Aug; 31(8):837-845. PubMed ID: 29975666
[TBL] [Abstract][Full Text] [Related]
12. Effect of Genotype and Previous GH Treatment on Adiposity in Adults With Prader-Willi Syndrome.
Coupaye M; Tauber M; Cuisset L; Laurier V; Bieth E; Lacorte JM; Oppert JM; Clément K; Poitou C
J Clin Endocrinol Metab; 2016 Dec; 101(12):4895-4903. PubMed ID: 27662437
[TBL] [Abstract][Full Text] [Related]
13. Somatropin therapy in adults with Prader-Willi syndrome.
Höybye C; Thorén M
Treat Endocrinol; 2004; 3(3):153-60. PubMed ID: 16026111
[TBL] [Abstract][Full Text] [Related]
14. Prader-Willi syndrome is associated with activation of the innate immune system independently of central adiposity and insulin resistance.
Viardot A; Sze L; Purtell L; Sainsbury A; Loughnan G; Smith E; Herzog H; Steinbeck K; Campbell LV
J Clin Endocrinol Metab; 2010 Jul; 95(7):3392-9. PubMed ID: 20444923
[TBL] [Abstract][Full Text] [Related]
15. C-reactive protein levels in subjects with Prader-Willi syndrome and obesity.
Butler MG; Bittel DC; Kibiryeva N; Garg U
Genet Med; 2006 Apr; 8(4):243-8. PubMed ID: 16617245
[TBL] [Abstract][Full Text] [Related]
16. Exacerbation of BMI after cessation of growth hormone therapy in patients with Prader-Willi syndrome.
Oto Y; Tanaka Y; Abe Y; Obata K; Tsuchiya T; Yoshino A; Murakami N; Nagai T
Am J Med Genet A; 2014 Mar; 164A(3):671-5. PubMed ID: 24443368
[TBL] [Abstract][Full Text] [Related]
17. Postprandial metabolism in adults with Prader-Willi syndrome.
Purtell L; Viardot A; Sze L; Loughnan G; Steinbeck K; Sainsbury A; Herzog H; Smith A; Campbell LV
Obesity (Silver Spring); 2015 Jun; 23(6):1159-65. PubMed ID: 25958986
[TBL] [Abstract][Full Text] [Related]
18. Fat-Free Mass Is Better Related to Serum Uric Acid Than Metabolic Homeostasis in Prader-Willi Syndrome.
Marzullo P; Mele C; Minocci A; Mai S; Scacchi M; Sartorio A; Aimaretti G; Grugni G
Nutrients; 2020 Aug; 12(9):. PubMed ID: 32854398
[No Abstract] [Full Text] [Related]
19. Glucose uptake and perfusion in subcutaneous and visceral adipose tissue during insulin stimulation in nonobese and obese humans.
Virtanen KA; Lönnroth P; Parkkola R; Peltoniemi P; Asola M; Viljanen T; Tolvanen T; Knuuti J; Rönnemaa T; Huupponen R; Nuutila P
J Clin Endocrinol Metab; 2002 Aug; 87(8):3902-10. PubMed ID: 12161530
[TBL] [Abstract][Full Text] [Related]
20. Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hormone therapy.
Zipf WB
Acta Paediatr Suppl; 1999 Dec; 88(433):115-7. PubMed ID: 10626560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
